These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1023 related items for PubMed ID: 10815932

  • 21. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G, Caputo R, Damiano V, Fontanini G, Melisi D, Veneziani BM, Zunino F, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
    [Abstract] [Full Text] [Related]

  • 22. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A.
    J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
    [Abstract] [Full Text] [Related]

  • 23. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo.
    Hara F, Aoe M, Doihara H, Taira N, Shien T, Takahashi H, Yoshitomi S, Tsukuda K, Toyooka S, Ohta T, Shimizu N.
    Cancer Lett; 2005 Aug 08; 226(1):37-47. PubMed ID: 16004931
    [Abstract] [Full Text] [Related]

  • 24. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
    Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH.
    Clin Cancer Res; 2002 Nov 08; 8(11):3496-502. PubMed ID: 12429640
    [Abstract] [Full Text] [Related]

  • 25. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.
    Cancer Res; 2006 Apr 01; 66(7):3802-12. PubMed ID: 16585207
    [Abstract] [Full Text] [Related]

  • 26. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.
    Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, Mendelsohn J, Bianco AR, Tortora G.
    Int J Cancer; 2001 Jul 15; 93(2):172-8. PubMed ID: 11410862
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
    Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP.
    Clin Cancer Res; 2002 May 15; 8(5):1253-64. PubMed ID: 12006546
    [Abstract] [Full Text] [Related]

  • 28. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
    Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH.
    Cancer Res; 2002 Oct 15; 62(20):5749-54. PubMed ID: 12384534
    [Abstract] [Full Text] [Related]

  • 29. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
    Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello F.
    Clin Cancer Res; 1999 Apr 15; 5(4):875-81. PubMed ID: 10213224
    [Abstract] [Full Text] [Related]

  • 30. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
    Sini P, Wyder L, Schnell C, O'Reilly T, Littlewood A, Brandt R, Hynes NE, Wood J.
    Clin Cancer Res; 2005 Jun 15; 11(12):4521-32. PubMed ID: 15958638
    [Abstract] [Full Text] [Related]

  • 31. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 32. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
    She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, Kris MG, Sirotnak FM.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3773-8. PubMed ID: 14506170
    [Abstract] [Full Text] [Related]

  • 33. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
    Ren W, Korchin B, Zhu QS, Wei C, Dicker A, Heymach J, Lazar A, Pollock RE, Lev D.
    Clin Cancer Res; 2008 May 01; 14(9):2785-95. PubMed ID: 18451246
    [Abstract] [Full Text] [Related]

  • 34. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.
    Kuwahara Y, Hosoi H, Osone S, Kita M, Iehara T, Kuroda H, Sugimoto T.
    Clin Cancer Res; 2004 Sep 01; 10(17):5940-8. PubMed ID: 15355927
    [Abstract] [Full Text] [Related]

  • 35. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
    Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL.
    Cancer Chemother Pharmacol; 2000 Sep 01; 45(3):231-8. PubMed ID: 10663641
    [Abstract] [Full Text] [Related]

  • 36. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
    Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, Cui J, Sun L, Wei J, Cherrington JM, Mendel DB.
    Clin Cancer Res; 2001 Dec 01; 7(12):4230-8. PubMed ID: 11751524
    [Abstract] [Full Text] [Related]

  • 37. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.
    Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ.
    Clin Cancer Res; 1998 Dec 01; 4(12):2957-66. PubMed ID: 9865906
    [Abstract] [Full Text] [Related]

  • 38. Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo.
    Li J, Li Y, Feng ZQ, Chen XG.
    Cancer Lett; 2009 Jul 08; 279(2):213-20. PubMed ID: 19299077
    [Abstract] [Full Text] [Related]

  • 39. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H.
    Biochem Pharmacol; 2005 Nov 25; 70(11):1568-78. PubMed ID: 16226226
    [Abstract] [Full Text] [Related]

  • 40. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Rose WC, Kramer RA, Wild R, Lee FY.
    Cancer Chemother Pharmacol; 2005 Nov 25; 56(5):455-64. PubMed ID: 15947929
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.